
Co-founder
This creation is the result of a collaboration between Romain Legrand, founder and director of the company, and Patrick Dallemagne and Christophe Rochais, co-founders and eminent teacher-researchers in medical chemistry at the Center for Studies and Research on Medicines. Normandy (CERMN) at the University of Caen Normandy.
These researchers have developed a drug candidate, Neocoprid , which belongs to the category of multi-target directed ligands (MTDL) with dual action on two targets involved in Alzheimer’s disease.